Enalapril improves obesity associated liver injury ameliorating systemic metabolic markers by modulating Angiotensin Converting Enzymes ACE/ACE2 expression in high-fat feed mice

Página do item simplificado
dc.creatorDaniel Silva Moraes
dc.creatorDeborah de Farias Lelis
dc.creatorJoão Marcus Oliveira Andrade
dc.creatorLara Meyer
dc.creatorAndré Luiz Senna Guimarães
dc.creatorAlfredo Maurício Batista de Paula
dc.creatorLucyana Conceição Farias
dc.creatorSérgio Henrique Sousa Santos
dc.date.accessioned2022-09-08T15:56:48Z
dc.date.accessioned2025-09-09T01:07:20Z
dc.date.available2022-09-08T15:56:48Z
dc.date.issued2021-02
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.identifier.doihttps://doi.org/10.1016/j.prostaglandins.2020.106501
dc.identifier.issn2212-196X
dc.identifier.urihttps://hdl.handle.net/1843/45007
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofProstaglandins and Other Lipid Mediators
dc.rightsAcesso Restrito
dc.subjectObesidade
dc.subjectSistema renina-angiotensina
dc.subjectEsteatose hepática
dc.titleEnalapril improves obesity associated liver injury ameliorating systemic metabolic markers by modulating Angiotensin Converting Enzymes ACE/ACE2 expression in high-fat feed mice
dc.typeArtigo de periódico
local.citation.spage106501
local.citation.volume152
local.description.resumoObesity is a chronic disease caused multiple associated factors that results in excessive body fat accumulation. The Renin-Angiotensin System (RAS) unbalance is now recognized as a key factor on regulating body energy and metabolism. Aim: the aim of the present study was to evaluate the Enalapril (ACE inhibitor) effects on the metabolic function and hepatic steatosis of obese mice evaluating Angiotensin Converting Enzymes (ACEs) expression. Methods: the experiment was performed using 32 male Swiss mice (8 weeks old) equally and randomly divided into 4 groups (n = 8): standard diet (ST), standard diet plus Enalapril (ST + ENAL), hyperlipidic diet (HF) and hyperlipidic diet plus Enalapril (HF + ENAL). Weekly measurements of animal weight and feed consumption were performed. At the end of treatment period a glucose tolerance test (GTT) and insulin sensitivity test (IST) were performed. Ultrasonography was used to evaluate hepatic and epididymal fat pad. Liver samples were submitted to HE histology and gene expression analyses were performed using Real-Time PCR. Results: the main results showed a decrease in body weight after treatment with Enalapril, as well as a reduced size of epididymal fat pad (EFP). Hepatic echogenicity and steatosis measurement were lower in the obese groups treated with Enalapril also modulating ACE2/ACE expressions. Conclusions: Enalapril use improved metabolism reducing hepatic steatosis, decreasing ACE expression and increasing ACE2 expression.
local.publisher.countryBrasil
local.publisher.departmentICA - INSTITUTO DE CIÊNCIAS AGRÁRIAS
local.publisher.initialsUFMG
local.url.externahttps://www.sciencedirect.com/science/article/pii/S1098882320300940?via%3Dihub

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG